Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases

BACKGROUND: Bone metastases are common in patients with hormone-refractory prostate cancer. In a study of autopsies of patients with prostate cancer, 65%-75% had bone metastases. Bone metastases place a substantial economic burden on payers with estimated total annual costs of $1.9 billion in the Un...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Jipan, Namjoshi, Madhav, Wu, Eric Q., Parikh, Kejal, Diener, Melissa, Yu, Andrew P., Guo, Amy, Culver, Kenneth W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2011
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437654/
https://www.ncbi.nlm.nih.gov/pubmed/21942303
http://dx.doi.org/10.18553/jmcp.2011.17.8.621

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437654/
https://www.ncbi.nlm.nih.gov/pubmed/21942303
http://dx.doi.org/10.18553/jmcp.2011.17.8.621

Ejemplares similares